Alkem Laboratories launches new probiotic DSS for gut health in India

Alkem Laboratories Limited announced the launch of "DSS," the original De Simone formulation probiotic blend, in India on November 20, 2025. This probiotic aims to restore gut microbiota balance and manage a spectrum of gut-related health conditions. The formulation, developed by Professor Claudio De Simone, combines eight bacterial strains and is supported by over 80 clinical trials and 200 publications.

The DSS range will be available in four strengths: 225 billion CFU sachet, 112.5 billion CFU capsule, 45 billion CFU capsule, and 10 billion CFU capsule. Alkem is the first company in India to offer all four strengths and holds exclusive marketing rights for the 225 billion CFU and 10 billion CFU strengths. The product is indicated for conditions such as Irritable Bowel Syndrome, Ulcerative Colitis, Pouchitis, and Non-Alcoholic Fatty Liver Disease.

The launch underscores Alkem's commitment to providing innovative health solutions, recognizing the growing focus on gut health in India. The Indian prescription probiotic market is valued at approximately INR 2,071 crore (MAT October 2025), with a five-year CAGR of around 14%, indicating strong demand driven by increasing consumer awareness and lifestyle-related digestive issues.